Monitorización de las superficies de trabajo de medicamentos peligrosos en los Servicios de Farmacia. Documento de consenso. Guía de práctica farmacéutica de la Sociedad Española de Farmacia Hospitalaria (SEFH)
Resumen
Objetivo: Establecer unas recomendaciones, en base a la evidencia disponible, para la monitorización de la contaminación de superficies en las áreas de elaboración de medicamentos peligrosos de los Servicios de Farmacia.
Método:A partir de una revisión bibliográfica en las bases de datos Medline y Embase desde enero de 2009 a julio de 2019, así como de la consulta de documentos de estándares y recomendaciones de organizaciones sanitarias, un comité de expertos de la Sociedad Española de Farmacia Hospitalaria ha definido una serie de prácticas seguras sobre manipulación de medicamentos peligrosos y monitorización de superficies de trabajo. Las decisiones de recomendación se tomaron por consenso entre el grupo de expertos teniendo en cuenta las recomendaciones encontradas, la situación en nuestro entorno y los costes asociados a la monitorización.
Resultados: Se han definido 10 recomendaciones estructuradas en ocho secciones. Se incluyen aspectos relacionados con los medicamentos a monitorizar; localizaciones a monitorizar; momento de la toma de muestras; determinación del riesgo y plan de muestreo; técnicas analíticas; umbrales de contaminación; plan de acción según los resultados del muestreo y descontaminación.
Conclusiones: La monitorización de superficies permite determinar la presencia de medicamentos peligrosos y evaluar la eficacia del programa de manejo seguro de los mismos en los Servicios de Farmacia. La evaluación debería incluir un estudio de la eficacia de los controles de ingeniería, de las prácticas laborales y de los procesos de limpieza y descontaminación.
Palabras clave
Referencias
McDevitt JJ, Lees PSJ, McDiarmid MA. Exposure of hospital pharmacists and nurses to antineoplastic agents. J Occup Med. 1993; 35:57-60.
Connor TH, Anderson RW, Sessink PJM, Broadfield L, Power LA. Surface contamination with antineoplastic agents in six cancer treatment centers in the United States and Canada. Am J Health- Syst Pharm. 1999;56:1427-32.
Sessink PJM, Anzion RB, Van den Broek PHH, Bos RP. Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Wkly (Sci). 1992;14:16-22.
Sessink PJM, Van de Kerkhof MCA, Anzion RB, Noordhoek J, Bos RP. Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: Is skin absorption an important exposure route? Arch Environ Health. 1994;49:165-9.
Sessink PJM, Friemèl NSS, Anzion RBM, Bos RP. Biological and environmental monitoring of occupational exposure of pharmaceutical plant workers to methotrexate. Int Arch Occup Environ Health. 1994;65:401-3.
Sessink PJM, Wittenhorst BCJ, Anzion RBM, Bos RP. Exposure of pharmacy technicians to antineoplastic agents: reevaluation after additional protective measures. Arch Environ Health. 1997;52:240- 4.
Valanis B, Vollmer WM, Steele P. Occupational exposure to antineoplastic agents: self-reported miscarriages and stillbirths among nurses and pharmacists. J Occup Environ Med. 1999;41(8):632-8.
Dranitsaris G, Jonhston M, Poirier S, Schueller T, Milliken D, Green E, et al. Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta- analysis of the literature. J Oncol Pharm Pract. 2005;11(2):69-78. DOI: 10.1191/1078155205jp155oa
McDiarmid MA, Oliver MS, Roth TS, Rogers B, Escalante C. Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs. J Occup Environ Med. 2010;52(10):1028-34. DOI: 10.1097/JOM.0b013e3181f73ae6
El-Ebiary AA, Abuelfadl AA, Sarhan NI. Evaluation of genotoxicity included by exposure to antineoplàstic drugs in lymphocytes of oncology nurses and pharmacists. J Appl Toxicol. 2013;33:196-201. DOI: 10.1002/jat.1735
Connor TH, Lawson CC, Polovish M, McDiarmid MA. Reproductive health risks associated with occupational exposures to antineoplastic drugs in health care settings. J Occup Environ Med. 2014;56:901- 10. DOI: 10.1097/JOM.0000000000000249
United States Pharmacopeial Convention. <800> Hazardous Drugs-Handling in Healthcare Settings. United States Pharmacopeia 42–National Formulary 37. Rockville, MD: US Pharmacopeial Convention; 2019.
Centers for disease control and prevention CDC. The National Institute for Occupational Safety and Health (NIOSH) [página web]. U.S. Department of Health & Human Services [accessed 8/25/2019]. Available at: https://www.cdc.gov/niosh/
International Society of Oncology Pharmacy Practitioners Standards Committee. ISOPP Standards of Practice. Safe handling of cytotoxics. J Oncol Pharm Pract. 2007;13:1-81.
Power LA, Coyne JW. ASHP Guidelines on Handling Hazardous Drugs. Am J Health-Syst Pharm. 2018;75(24):1996-2031.
Occupational Safety and Health Administration (OSHA). Controlling Occupational Exposure to Hazardous Drugs. OSHA Technical Manual, Sección VI, Capítulo 2 [Internet]. U.S. Occupational Safety and Health Administration (OSHA); 2016 [accessed 8/27/2019]. Available at: www.osha.gov/SLTC/hazardousdrugs/controlling_occex_hazardousdrugs.html
National Association of Pharmacy Regulatory Authorities (NAPRA). Model Standards for Pharmacy Compounding of Hazardous Sterile Preparations [Internet]. Ottawa, Canadá: National Association of Pharmacy Regulatory Authorities (NAPRA); 2016 [accessed 8/27/2019]. Available at: napra.ca/sites/default/files/2017-09/Mdl_Stnds_Pharmacy_Compounding_Hazardous_Sterile_Preparat ions_Nov2016_Revised_b.pdf
Burroughs G, Connor T, McDiarmid M. NIOSH alert: preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings [Internet]. DHHS (NIOSH) Publ No. 2004-165 [accessed 8/25/2019]. Available at: http://www.cdc.gov/niosh/docs/2004-165/pdfs/2004-165.pdf
Polovich M, Olsen MM. Safe Handling of Hazardous Drugs, 3.ª ed. Pittsburgh, PA: Oncology Nursing Society; 2018.
Connor TH, DeBord G, Pretty JR, Oliver MS, Roth TS, Lees PS, et al. Evaluation of antineoplastic drug exposure of health care workers at three university-based US cancer centers. J Occup Environ Med. 2010;52:1019-27. DOI: 10.1097/JOM.0b013e3181f72b63
Valero-García S, Poveda-Andrés JL, Grupo multicéntrico de análisis de contaminación por medicamentos peligrosos en superficies de trabajo de Servicios de Farmacia Hospitalaria españoles. Hazardous drugs levels in compounding area surfaces of Hospital Pharmacies Services: multicentric study. Farm Hosp. 2018;42(4):152-8.
Wick C, Slawson MH, Jorgenson JA, Tyler LS. Using a closed- system protective device to reduce personnel exposure to antineoplastic agents. Am J Health-Syst Pharm. 2003;60:2314-20.
Harrison BR, Peters BG, Bing MR. Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques. Am J Health-Syst Pharm. 2006;63:1736-44.
Sessink PJM, Connor TH, Jorgenson JA, Tyler TG. Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device. J Oncol Pharm Pract. 2011;17:39-48.
Sessink PJM, Trahan J, Coyne JW. Reduction in surface contamination with cyclophosphamide in 30 US hospital pharmacies following implementation of a closedsystem drug transfer device. Hosp Pharm. 2013;48:204-12.
Sessink PJM, Leclercq GM, Wouters DM, Halbardier L, Hammad C, Kassoul N. Environmental contamination, product contamination and workers exposure using a robotic system for antineoplastic drug preparation. J Oncol Pharm Pract. 2015;21(2):118-27.
Ashley K, Brisson MJ, White KT. Review of standards for surface and dermal sampling. J ASTM Intl. 2011;8(6):1-9.
Kiffmeyer TK, Tuerk J, Hahn M, Stuetzer H, Hadtstein C, Heinemann A, et al. Application and Assessment of a Regular Environmental Monitoring of the Antineoplastic Drug Contamination Level in Pharmacies – The MEWIP Project. Ann Occup Hyg. 2013;57(4):444-55.
Salch SA, Zamboni W, Zamboni B, Eckel S. Patterns and Characteristics Associated with Surface Contamination of Hazardous Drugs in Hospital Pharmacies. Am J Health-Syst Pharm. 2019;76(9):591-8.
Connor T, Zock M, Snow A. Surface Wipe Sampling for Antineoplastic (Chemotherapy) and Other Hazardous Drug Residue in Healthcare Settings: Methodology and Recommendations. J Occup Environ Hyg. 2016;13(9):658-67.
Cone C, Felton LA, Bachyrycz A. Pharmaceutical compounding – USP <797> Sterile preparations. En: Felton L. Essentials of Pharmaceutics. Albuquerque, NM, USA: Remington Pharmaceutical Press; 2013. p. 533-41.
Sessink PJM, Sewell G, Vandenbroucke J. Preventing occupational exposure to cytotoxic and other hazardous drugs. European Policy Recommendations. [Internet]. Bruseles: European Parliament; 2015 [accessed 8/25/2019]. Available at: https://www.europeanbiosafetynetwork.eu/wp-content/uploads/2016/05/Exposure-to-Cytotoxic- Drugs_Recommendation_DINA4_10-03-16.pdf
Instituto Nacional de Seguridad e Higiene en el Trabajo (INSHT). Medicamentos Peligrosos. Medidas de prevención para su preparación y administración. Documentos Técnicos [Internet]. Ministerio de Empleo y Seguridad Social. 2016 [accessed 8/25/2019]. Available at: http://www.enfermeriadeurgencias.com/images/archivos/DOC- 20161123-WA0036.pdf
Instituto Nacional de Seguridad, Salud y Bienestar en el Trabajo. Información para trabajadores sanitarios sobre medicamentos peligrosos. Base de datos INFOMEP. Ministerio de Empleo y Seguridad Social [accessed 8/25/2019]. Available at: http://infomep.inssbt.es
Real Decreto 374/2001, de 6 de abril. Sobre la protección de la salud y seguridad de los trabajadores contra los riesgos relacionados con los agentes químicos durante el trabajo. Boletín Oficial del Estado, nº 104 (1 de mayo de 2001).
Real Decreto 665/1997, de 12 de mayo. Sobre la protección de los trabajadores contra los riesgos relacionados con la exposición a agentes cancerígenos durante el trabajo. Boletín Oficial del Estado, nº 124 (24 de mayo de 1997).
Ley 31/1995, de 8 de noviembre, de Prevención de Riesgos Laborales. Boletín Oficial del Estado, nº 269 (10 de noviembre de 1995).
Real Decreto 824/2010, de 25 de junio, por el que se regulan los laboratorios farmacéuticos, los fabricantes de principios activos de uso farmacéutico y el comercio exterior de medicamentos y medicamentos en investigación. Boletín Oficial del Estado, nº 165 (8 de julio de 2010).
Guichard N, Rudaz S, Bonnabry P, Fleury-Souverain S. Validation and uncertainty estimation for trace amounts determination of 25 drugs used in hospital chemotherapy compounding units. J Pharm Biomed Anal. 2019;172:139-48.
Guichard N, Feketea S, Guillarme D, Bonnabry P, Fleury- Souverain S. School Computer-assisted UHPLC–MS method development and optimization for the determination of 24 antineoplastic drugs used in hospital pharmacy. J Pharm Biomed Anal. 2019;164:395-401.
Valero S, Vila N, Fornés V, López-Briz E, Poveda JL. Use and handling safety of Mini-Spike 2® Chemo and Puresite for safe chemotherapy compounding in a hospital pharmacy. Regul Toxicol Pharmacol. 2018;100:1-6. DOI: https://doi.org/10.1016/j.yrtph.2018.10.002
Crul M, Simons-Sanders K. Carry-over of antineoplastic drug contamination in Dutch hospital pharmacies. J Oncol Pharm Pract. 2017;24(7):483-9. DOI: 10.1177/1078155217704990
Poupeau C, Tanguay C, Caron NJ, Bussieres JF. Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals study. J Oncol Pharm Practice. 2018;24(1):9-17. DOI: 10.1177/1078155216676632
Roland C, Caron N, Bussières JF. Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: A 2016 follow-up study. J Occup Environ Hyg. 2017;14(8):661-9. DOI 10.1080/15459624.2017.1316389
Martín Lancharro P, de Castro-Acuña Iglesias N, González- Barcala FJ, Moure González JD. Evidence of exposure to cytostatic drugs in healthcare staff: a review of recent literature. Farm Hosp. 2016;40(6):604-21.
Fleury-Souverain S, Mattiuzzo M, Mehl F, Nussbaumer S, Bouchoud L, Falaschi L, et al. Evaluation of chemical contamination of surfaces during the preparation of chemotherapies in 24 hospital pharmacies. Eur J Hosp Pharm. 2015;22:333-41. DOI: 10.1136/ejhpharm-2014-000549
Ramphal R, Bains T, Goulet G, Vaillancourt R. Occupational Exposure to Chemotherapy of Pharmacy Personnel at a Single Centre. Can J Hosp Pharm. 2015;68(2):104-12.
Berruyer M, Tanguay C, Caron NJ, Lefebvre M, Bussieres JF. Multicenter Study of Environmental Contamination with Antineoplastic Drugs in 36 Canadian Hospitals: A 2013 Follow-up Study. J Occup Environ Hyg. 2015;12: 87-94.
Hon CH, Teschke K, Demers PA, Venners S. Antineoplastic Drug Contamination on the Hands of Employees Working Throughout the Hospital Medication System Ann Occup Hyg. 2014;58(6):761-70. DOI: 10.1093/annhyg/meu019
Órás Z, Szölgyémi MK, Higyisán I. Analysis of environmental contamination in the central cytostatics department. Eur J Oncol Pharmacy. 2014;8(3):22-5.
Sato J, Mori M, Sasaki T, Nihei S, Kumagai M, Nakayama S, et al. Field survey of the anticancer drug contamination in the preparation environment. Usefulness of the 5-FU monitoring by the coupon method. Journal of the Pharmaceutical Society of Japan. 2014;134(6):751-6.
Odraska P, Dolezalova L, Kuta J, Oravec M, Piler P, Synek S, et al. Association of surface contamination by antineoplastic drugs with different working conditions in hospital pharmacies. Arch Environ Occup Health. 2014; 69:148-58.
Hon Ch, Teschke K, Chu W, Demers P, Venners S. Antineoplastic Drug contamination of Surfaces Throughout the Hospital Medication System in Canadian Hospitals. J Occup Environ Hyg. 2013;10:374- 83.
Korczowska E, Jankowiak-Gracz H. How can we improve safe handling of antineoplastic drugs: can devices be helpful. Eur J Oncol Pharmacy. 2013;7(1):5-7.
Sabatini L, Barbieri A, Lodi V, Violante FS. Biological monitoring of occupational exposure to antineoplastic drugs in hospital Settings. Med Lav. 2012;103(5):394‑401.
Mattiuzzo M, Nussbaumer S, Sadeghipour S, Fleury-Souverain S, Bonnabry P. Cytotoxic surface contamination in 24 swiss hospital pharmacies. European Journal of Hospital Pharmacy. 2012;19(2):144. DOI: 10.1136/ejhpharm-2012-000074.157
Chu WC, Hon Ch, Danyluk Q, Chua PS, Astrakianakis G. Pilot assessment of the antineoplastic drug contamination levels in British Columbian hospitals pre- and post-cleaning. J Oncol Pharm Practice. 2011;18(1):46-51.
Hon ChY, Astrakianakis G, Danyluk Q, Chu W. Pilot Evaluation of Dermal Contamination by Antineoplastic Drugs among Hospital Pharmacy Personnel. Can J Hosp Pharm. 2011;64(5):327-32.
Sottani C, Porro B, Comelli M, Imbriani M, Minoia C. An analysis to study trends in occupational exposure to antineoplastic drugs among health care workers. J Chromatogr B Analyt Technol Biomed Life Sci. 2010; 878(27):2593-605.
Blaha L, Odraska P, Dolezalova L, Piler P, Prudilova M, Vejpustková R, et al. Exposures and risks of antineoplastic drugs to hospital workers: Complex evaluation of monitoring and biomonitoring data. Journal of Oncology Pharmacy Practice. 2010;16:2 suppl. 1:15-6.
Odraska P, Dolezalova L, Gorna L, Prudilova M, Vejpustkova R, Kuta J, et al. Nation-wide monitoring of surface contamination by cyclophosphamide and platinum drugs in hospital pharmacies in the Czech Republic. Journal of Oncology Pharmacy Practice. 2010;16(2) suppl. 1:30-1.
Touzin K, Bussières JF, Langlois E, Lefebvre M, Métra A. Pilot study comparing the efficacy of two cleaning techniques in reducing environmental contamination with cyclophosphamide. Ann Occup Hyg. 2010;54(3):351-9. DOI: 10.1093/annhyg/meq004
Brouwers EEM, Huitema ADR, Schellens JHM, Beijnen JH. Development, validation and application of an inductively coupled plasma mass spectrometry method for the determination of platinum in wipe samples. Pharmaceutisch Weekblad. 2010;145(7):25-8.
Siderov J, Kirsa S, McLauchlan R. Surface contamination of cytotoxic chemotherapy preparation areas in Australian Hospital Pharmacy Departments. Journal of Pharmacy Practice and Research. 2009;39(2):117-21.
Touzin K, Bussieres JF, Langlois É, Lefebvre M. Evaluation of surface contamination in a hospital hematology-oncology pharmacy. J Oncol Pharm Pract. 2009;15(1):53‑61. DOI: 10.1177/1078155208096904
Valero S, López-Briz E, Vila N, Solana A, Melero M, Poveda JL. Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process. Regul Toxicol Pharmacol. 2018;95:1-7. DOI: 10.1016/j.yrtph.2018.03.001
Bartel SB, Tyler TG, Power LA. Multicenter evaluation of a new closed system drugtransfer device in reducing surface contamination by antineoplastic hazardous drugs. Am J Health Syst Pharm. 2018;75:199-211.
Bobin-Dubigeon C, Aminad M, Percheron C, Audeval C, Rochard S, Leynia P, et al. A new validated wipe-sampling procedure coupled to LC-MS analysis for the simultaneous determination of 5- Fluorouracil, Doxorubicin and Cyclophosphamide in surface contamination. J Anal Toxicol. 2013;37:433-9.
Bussieres JF, Tanguay C, Touzin K, Langlois E, Lefebvre M. Environmental contamination with hazardous drugs in Quebec hospitals. Can J Hosp Pharm. 2012;65:428‑35.
Dal Bello F, Santoro V, Scarpino V, Martano C, Aigotti R, Chiappa A, et al. Antineoplastic drugs determination by HPLC-HRMSn to monitor occupational exposure. Drug Test Anal. 2016; 8:730-7.
Fabrizi G, Fioretti M, Rocca LM, Curini R. DESI-MS2: a rapid and innovative method for trace analysis of six cytostatic drugs in health care setting. Anal Bioanal Chem. 2012;403:973-83.
Jeronimo M, Colombo M, Astrakianakis G, Hon CY. A surface wipe sampling and LC-MS/MS method for the simultaneous detection of six antineoplastic drugs commonly handled by healthcare workers. Anal Bioanal Chem. 2015;407:7083-92. DOI: 10.1007/s00216-015-8868-y
Kibby T. A review of surface wipe sampling compared to biologic monitoring for occupational exposure to antineoplastic drugs. J Occup Environ Hyg. 2017;14:159‑74.
Koller M, Böhlandt A, Haberl C, Nowak D, Schierl R. Environmental and biological monitoring on an oncology ward during a complete working week. Toxicol Letters. 2018;298:158-63.
Kopp B, Schierl R, Nowak D. Evaluation of working practices and surface contamination with antineoplastic drugs in outpatient oncology health care settings. Int Arch Occup Environ Health. 2013;86:47-55.
Müller-Ramírez C, Squibb K, McDiarmid M. Measuring extent of surface contamination produced by the handling of antineoplastic drugs in low-to-middle-income country oncology health care settings. Arch Occup Environ Health. 2017;72:289‑98.
Nussbaumer S, Geiser L, Sadeghipour F, Hochstrasser D, Bonnabry P, Veuthey JL, et al. Wipe sampling procedure coupled to LC-MS/MS analysis for the simultaneous determination of 10 cytotoxic drugs on different surfaces. Anal Bioanal Chem. 2012;402:2499-509.
Panahi D, Azari M, Akbari ME, Zendehdel R, Mirzaei HR, Hatami H, et al. Development of a new method for sampling and monitoring oncology staff exposed to cyclophosphamide drug. Environ Monit Assess. 2016;188:238-43.
Pretty JR, Connor TH, Spasojevic I, Kurtz KS, McLaurin JL, B’ Hymer C, et al. Sampling and mass spectrometric analytical methods for five antineoplastic drugs in the healthcare environment. J Oncol Pharm Pract. 2010;18:23-36.
Simon N, Vasseur M, Pinturaud M, Soichot M, Richeval C, Humbert L, et al. Effectiveness of a closed-system transfer device in reducing surface contamination in a new antineoplastic drug compounding unit: a prospective, controlled, parallel study. PLOS ONE. 2016;11:e0159052.
Viegas S, Padua M, Veiga AC, Carolino E, Gomes M. Antineoplastic drugs contamination of workplace surfaces in two Portuguese hospitals. Environ Monit Assess. 2014;186 (11):7807- 18. DOI: 10.1007/s10661-014-3969-1
Huang YW, Zhang NH, Tong DM, Feng X, Zhang MB, He JL. Investigation on occupational exposure to 5-fluorouracil in pharmacy intravenous admixture service of a hospital. Chinese Journal of Industrial Hygiene and Occupational Diseases. 2010;28(6):414-7.
Schierl R, Hlandt AB, Nowak D. Guidance Values for Surface Monitoring of Antineoplastic Drugs in German Pharmacies. Ann Occup Hyg. 2009;53(7):703-11. DOI: 10.1093/annhyg/mep050
Smith JP, Sammons DL, Robertson SA, Pretty J, Debord DG, Connor TH, et al. Detection and measurement of surface contamination by multiple antineoplastic drugs using multiplex bead assay. J Oncol Pharm Pract. 2016;22(1):60-7. DOI: 10.1177/1078155214554407
Odráška P, Gorná L, Doležalová L, Oravec M, Kuta J, Bláha L. Monitoring of surface cytotoxic drugs in the environment of hospital pharmacies in the Czech Republic. Ceska a Slovenska Farmacie. 2009;58(5-6):225-9.
Sessink PJM. Reference values for environmental contamination with cyclophosphamide (CP) in the Netherlands. Safety Consideration in Oncology Pharmacy. Special Edition; Fall 2011:3-5.
American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm. 1990;47:1033-49.
Kimmel TA, Sussman RG, Ku RH, Adar AW. Developing acceptable surface limits for occupational exposure to pharmaceutical substances. J ASTM Intl. 2011;8(8):1-6. DOI: 10.1520/JAI103480
Connor TH, Massoomi F. Environmental monitoring and medical surveillance of health care workers who handle hazardous drugs (HDs). En: Mansur J, ed. Improving Safe Handling Practices for Hazardous Drugs. Oak Brook, IL: Joint Commission Resources; 2016. p. 140-9.
Yoshida J, Koda S, Nishida S, Nakano H, Tei G, Kumagai S. Association between occupational exposure and control measures for antineoplastic drugs in a pharmacy of a hospital. Ann Occup Hyg. 2013;57(2):251-60. DOI: 10.1093/annhyg/mes061
Bourget P, Amin A, Vidal F, Merlette C, Troude P, Baillet-Guffroy A. The contribution of Raman spectroscopy to the analytical quality control of cytotoxic drugs in a hospital environment: Eliminating the exposure risks for staff members and their work environment. Int J Pharm. 2014;470(1-2):70-6. DOI: 10.1016/j.ijpharm.2014.04.064
Sajid M, Kawde A, Daud M. Designs, Formats and Applications of Lateral Flow Assay: A Literature Review. J Saudi Chem Soc. 2015;19(6):689-705.
Senssink PJM. Kroese ED, van Kranen HJ, Bos RP. Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Intern Arch Occup Environ Health. 1995;67:317- 23.
Hedmer M, Wohlfart G. Hygienic Guidance Values for Wipe Sampling of Antineoplastic Drugs in Swedish Hospitals. J Environ Monit. 2012;14:1968-75.
Acampora A, Castiglia L, Miraglia N, Pieri M, Soave C, Liotti F, et al. A case study: surface contamination of cyclophosphamide due to working practices and cleaning procedures in two Italian hospitals. Ann Occup Hyg. 2005;49:611-8. DOI: 10.1093/annhyg/mei029
Queruau Lamerie T, Nussbaumer S, DéCAuDin B, Fleury- Souverain S, Goossens JF, Bonnabry P, et al. Evaluation of Decontamination Efficacy of Cleaning Solutions on Stainless Steel and Glass Surfaces Contaminated by 10 Antineoplastic Agents. Ann Occup Hyg. 2013;57(4):456-69. DOI: 10.1093/annhyg/mes087
Böhlandt A, Groeneveld S, Fischer E, Schierl R. Cleaning efficiencies of three cleaning agents on four different surfaces after contamination by gemcitabine and 5-fluorouracil. J Occup Environ Hyg. 2015;12:384-92. DOI: 10.1080/15459624.2015.1009985
Lê LMM, Jolivot PA, Sadou Yaye H, Rieutord A, Bellanger A, Pradeau D, et al. Effectiveness of Cleaning of Workplace Cytotoxic Surface. Int Arch Occup Environ Health. 2013;86:333-41. DOI: 10.1007/s00420-012-0769-1
Hon CY, Chua PP, Danyluk Q, Astrakianakis G. Examining factors that influence the effectiveness of cleaning antineoplastic drugs from drug preparation surfaces: a pilot study. J Oncol Pharm Pract. 2014;20:210-6. DOI: 10.1177/1078155213497070
Benvenuto JA, Connor T, Monteith DK, Laidlaw JL, Adams SC, Matney TS, et al. Degradation and inactivation of antitumor drugs. J Pharm Sci. 1993;82:988‑91. DOI: 10.1002/jps.2600821003
Simon N, Odou P, Decaudin B, Bonnabry P, Fleury-Souverain S. Efficiency of degradation or desorption methods in antineoplastic drug decontamination: A critical review. J Oncol Pharm Pract. 2019;25(4):929-46. DOI: 10.1177/1078155219831427
Gohma H, Inoue Y, Asano M, Sugiura SI. Testing the degradation effects of three reagents on various antineoplastic compounds. J Oncol Pharm Pract. 2015;21:268-73. DOI: 10.1177/1078155214530175
Lee SG, Ambados F, Tkaczuk M, Jankewicz G. Paclitaxel exposure and its effective decontamination. J Pharm Pract Res. 2009;39:181-5. DOI: 10.1002/j.2055-2335.2009.tb00449.x
Barek J, Cvacka J, Zima J, De Méo M, Laget M, Michelon J, et al. Chemical degradation of wastes of antineoplastic agents amsacrine, azathioprine, asparaginase and thiotepa. Ann Occup Hyg. 1998;42:259-66. DOI: 10.1016/S0003-4878(98)00023-4
Castagnero M, De Méo M, Laget M, Michelon J, Garren L, Sportouch H, et al. Chemical degradation of wastes of antineoplastic agents. 2: six anthracyclines: idarubicin, doxorubicin, epirubicin, pirarubicin, aclarubicin, and daunorubicin. Int Arch Occup Environ Health. 1997;70:378-84. DOI: 10.1007/s004200050232
Hansel S, Castagnero M, Sportouch MH, De Méo M, Milhavet JC, Laget M, et al. Chemical degradation of wastes of antineoplastic agents: cyclophosphamide, ifosfamide and melphalan. Int Arch Occup Environ Health. 1997;69:109-14. DOI: 10.1007/s004200050124
Adé A, Chauchat L, Ouellette FJF, Gagné S, Caron N, Bussières JF. Comparison of decontamination efficacy of cleaning solutions on a biological safety cabinet workbench contaminated by cyclophosphamide. Can J Hosp Pharm. 2017;70:407-14. DOI: 10.4212/cjhp.v70i6.1708
DOI: http://dx.doi.org/10.7399%2Ffh.11655
Enlaces refback
- No hay ningún enlace refback.
Incluida en:
Farmacia Hospitalaria
Sociedad Española de Farmacia Hospitalaria. C/ Serrano n. 40 2º Dcha. - 28001 Madrid
eISSN: 2171-8695
ISSN-L: 1130-6343
Dep. Legal: M-39835-2012
Correo electrónico de contacto: [email protected]
Los artículos publicados en esta revista se distribuyen con la licencia: Creative Commons Attribution 4.0.
La revista Farmacia Hospitalaria no cobra tasas por el envío de trabajos, ni tampoco cuotas por la publicación de sus artículos.